Search

Your search keyword '"Zhang, Mu-Chen"' showing total 19 results
Start Over Author "Zhang, Mu-Chen"
19 results on '"Zhang, Mu-Chen"'

5. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial

Author

Zhang, Mu-Chen, primary, Tian, Shuang, additional, Fu, Di, additional, Wang, Li, additional, Cheng, Shu, additional, Yi, Hong-Mei, additional, Jiang, Xu-Feng, additional, Song, Qi, additional, Zhao, Yan, additional, He, Yang, additional, Li, Jian-Feng, additional, Mu, Rong-Ji, additional, Fang, Hai, additional, Yu, Hao, additional, Xiong, Hui, additional, Li, Biao, additional, Chen, Sai-Juan, additional, Xu, Peng-Peng, additional, and Zhao, Wei-Li, additional

Published
2023
Full Text
View/download PDF

7. Figure S1 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Author

Yan, Zi-Xun, primary, Li, Li, primary, Wang, Wen, primary, OuYang, Bin-Shen, primary, Cheng, Shu, primary, Wang, Li, primary, Wu, Wen, primary, Xu, Peng-Peng, primary, Muftuoglu, Muharrem, primary, Hao, Ming, primary, Yang, Su, primary, Zhang, Mu-Chen, primary, Zheng, Zhong, primary, Li, James, primary, and Zhao, Wei-Li, primary

Published
2023
Full Text
View/download PDF

8. Table S2 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Author

Yan, Zi-Xun, primary, Li, Li, primary, Wang, Wen, primary, OuYang, Bin-Shen, primary, Cheng, Shu, primary, Wang, Li, primary, Wu, Wen, primary, Xu, Peng-Peng, primary, Muftuoglu, Muharrem, primary, Hao, Ming, primary, Yang, Su, primary, Zhang, Mu-Chen, primary, Zheng, Zhong, primary, Li, James, primary, and Zhao, Wei-Li, primary

Published
2023
Full Text
View/download PDF

9. Data from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Author

Yan, Zi-Xun, primary, Li, Li, primary, Wang, Wen, primary, OuYang, Bin-Shen, primary, Cheng, Shu, primary, Wang, Li, primary, Wu, Wen, primary, Xu, Peng-Peng, primary, Muftuoglu, Muharrem, primary, Hao, Ming, primary, Yang, Su, primary, Zhang, Mu-Chen, primary, Zheng, Zhong, primary, Li, James, primary, and Zhao, Wei-Li, primary

Published
2023
Full Text
View/download PDF

10. Integrative genome‐wide chromatin accessibility and transcriptome profiling of diffuse large B‐cell lymphoma

Author

Fang, Ying, primary, Zhang, Mu‐Chen, additional, Xu, Peng‐Peng, additional, Zhang, Su‐Jiang, additional, Wang, Li, additional, Cheng, Shu, additional, Fu, Di, additional, Chang, Chun‐Kang, additional, Sun, Xiao‐Jian, additional, Zhao, Yan, additional, Tang, Yi‐Jia, additional, Tian, Xin, additional, Yi, Hong‐Mei, additional, Liu, Feng, additional, and Zhao, Wei‐Li, additional

Published
2022
Full Text
View/download PDF

11. Additional file 1 of Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma

Author

Huo, Yu-Jia, Xu, Peng-Peng, Wang, Li, Zhong, Hui-Juan, Fu, Di, Shi, Qing, Cheng, Shu, Wang, Shuo, Zhang, Mu-Chen, and Zhao, Wei-Li

Abstract

Additional file 1: Supplementary Methods. Figure S1. Dynamic change of sIL-2R in DLBCL. Figure S2. Univariate and multivariate risk models in DLBCL according to sIL-2R dynamic change. Figure S3. Survival analysis in DLBCL according to sIL-2R dynamic change in patients risked by R-IPI. Figure S4. Genetic and lymphoma microenvironment features of sIL-2R subtypes. Table S1. Clinical and pathological characteristics of DLBCL patients. Table S2. Multivariate analysis and C-index for progression-free survival (PFS) and overall survival (OS) in DLBCL. Table S3. Pathway alterations in RES subtype. Table S4. Pathway alterations in RET subtype.

Published
2022
Full Text
View/download PDF

13. Clinical efficacy and tumour microenvironment influence of decitabine plus R‐CHOP in patients with newly diagnosed diffuse large B‐Cell lymphoma: Phase 1/2 and biomarker study

Author

Zhang, Mu‐Chen, primary, Fang, Ying, additional, Xu, Peng‐Peng, additional, Dong, Lei, additional, Shen, Rong, additional, Huang, Yao‐Hui, additional, Fu, Di, additional, Yan, Zi‐Xun, additional, Cheng, Shu, additional, Jiang, Xu‐Feng, additional, Song, Qi, additional, He, Yang, additional, Zhao, Yan, additional, Lu, Min, additional, Ye, Jing, additional, Liu, Feng, additional, Cheng, Lin, additional, Wang, Chao‐Fu, additional, Wang, Li, additional, and Zhao, Wei‐Li, additional

Published
2021
Full Text
View/download PDF

15. Clinical Efficacy and Epigenetic Biomarkers in a Phase II Study of Chidamide Plus R-CHOP in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Author

Zhang, Mu-Chen, primary, Xu, Peng-Peng, additional, Fang, Ying, additional, Wang, Li, additional, Cheng, Shu, additional, Fu, Di, additional, He, Yang, additional, Zhao, Yan, additional, Wang, Chao-Fu, additional, Jiang, Xu-Feng, additional, Song, Qi, additional, and Zhao, Wei-Li, additional

Published
2020
Full Text
View/download PDF

16. Clinical Efficacy and Molecular Biomarkers of Chidamide Plus R-CHOP In Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: An Open-Label Phase II Clinical Trial

Author

Zhang, Mu-Chen, primary, Fang, Ying, additional, Wang, Li, additional, Cheng, Shu, additional, Fu, Di, additional, He, Yang, additional, Zhao, Yan, additional, Wang, Chao-Fu, additional, Jiang, Xu-Feng, additional, Song, Qi, additional, Xu, Peng-Peng, additional, and Zhao, Wei-Li, additional

Published
2020
Full Text
View/download PDF

17. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Author

Yan, Zi-Xun, primary, Li, Li, additional, Wang, Wen, additional, OuYang, Bin-Shen, additional, Cheng, Shu, additional, Wang, Li, additional, Wu, Wen, additional, Xu, Peng-Peng, additional, Muftuoglu, Muharrem, additional, Hao, Ming, additional, Yang, Su, additional, Zhang, Mu-Chen, additional, Zheng, Zhong, additional, Li, James, additional, and Zhao, Wei-Li, additional

Published
2019
Full Text
View/download PDF

19. [Advances in genetic studies of Charcot-Marie-Tooth disease type 4 (CMT4)].

Author

Xu Y, Zhang JY, Yang BY, He ZH, Zhang MC, Yu Z, and Gu MM

Subjects
Animals, Charcot-Marie-Tooth Disease classification, Disease Models, Animal, Genotype, Humans, Mice, Phenotype, Charcot-Marie-Tooth Disease genetics
Abstract

The Charcot-Marie-Tooth disease (CMT) is one of the most common human inherited peripheral neuropathies. The most common pattern of inheritance is autosomal dominant, with less often occurrence autosomal recessive and X-linked dominant/recessive inheritance. CMT is generally divided into three forms: demyelinating forms (CMT1), axonal forms (CMT2) and intermediate forms (DI-CMT). The autosomal recessive form (AR-CMT1 or CMT4) is accompanied by progressive distal muscle weakness and atrophy of the limbs, pes cavus and claw-like hands. In addition, CMT4 is also characterized by early onset, rapid progression, and varying degrees of sensory loss and spinal deformities (e.g. scoliosis). Recently, 11 subtypes of CMT4 have been identified. Some of these subtypes were clear in pathogenic mechanisms, some had founder mutation, but some still had limited clinical description and mutation analysis. In this review, we summarize the latest research progresses of CMT4, including genotypes and phenotypes, pathogenic mechanisms and mouse models.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results